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Objective: A cholesteatoma is a mass of keratinising epithelium in the middle ear. It
is a rare disorder that is associated with significant morbidity, and its causative risk
factors are poorly understood; on a global scale, up to a million people are affected
by this each year. We have conducted a systematic literature review to identify
reports about the heritability of cholesteatoma or any constitutional genetic factors
that may be associated with its aetiology.
Data Sources: A systematic search of MEDLINE (EBSCO) and two databases of
curated genetic research (OMIM and Phenopedia) was conducted.
Study Selection: The participants and populations of interest for this review were
people treated for cholesteatoma and their family members. The studies of interest
reported evidence of heritability for the trait, or any association with congenital syn-
dromes and particular genetic variants.
Data Extraction: The searches identified 449 unique studies, of which 35 were
included in the final narrative synthesis.
Data Synthesis: A narrative synthesis was conducted, and data were tabulated to
record characteristics, including study design, genetic data and author conclusions.
Most of the studies identified in the literature search, and described here, are case
reports and so represent the lowest level of evidence. In a few case reports, con-
genital and acquired cholesteatomas have been shown to segregate within families
in the pattern typical of a monogenic or oligogenic disorder with incomplete pene-
trance. Evidence from syndromic cases could suggest that genes controlling ear
morphology may be risk factors for cholesteatoma formation.
Conclusions: This is the first systematic review about the genetics of cholestea-
toma, and we have identified a small body of relevant literature that provides evi-
dence of a heritable component for its aetiology. Cholesteatoma is a complex and
heterogeneous clinical phenotype, and it is often associated with chronic otitis
media and with some rare congenital syndromes known to affect ear morphology
and related pathologies.
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1 | INTRODUCTION
A cholesteatoma is a self-perpetuating erosive lesion composed of
stratified keratinising squamous epithelium in the middle ear.1 Cho-
lesteatoma has both an acquired and a congenital form. It activates
osteoclasts and so will erode through bone, which may include the
endocranium, with an attendant risk of life-threatening intracranial
infection.
The acquired form of cholesteatoma originates as an inward
growth from the lateral epithelium of the tympanic membrane. A
typical sequence of events in the onset of the disease includes a
history of chronic otitis media (COM) in childhood, subsequent
development of retraction of the tympanic membrane and then a
cholesteatoma developing within and perforating through this
retraction. This seems to particularly occur if the retraction is
located in the superior tympanic membrane (pars flaccida).2-4 In
children with a history of chronic otitis media with effusion
(COME), 15-35% will develop a retraction of the pars flaccida (at
up to 25 years of follow-up), but only 0.1-2% will develop a cho-
lesteatoma (at up to 8 years of follow-up).4-7 Both presence and
duration of COME are predictive of tympanic membrane retrac-
tion,3,4 but tympanic retraction has been documented to occur in
the absence of preceding COME.4 However, histological studies
suggest that in such cases there is nevertheless chronic middle
ear inflammation, it is just not clinically apparent.8 Thus, cholestea-
toma is often preceded by COM, but only a small proportion of
those with COM will develop cholesteatoma. What determines the
transition from COM to cholesteatoma is not known, but could
be due to environmental factors, heritable factors or random
effects. But those who develop cholesteatoma have been reported
to have between a 7% and a 20% chance of developing disease
in the contralateral ear,9,10 highlighting the importance of shared
genes and shared environments.
Cholesteatoma can also be found behind an intact tympanic
membrane.11 This form is thought to be congenital, and may result
from persistence of the foetal epidermoid formation, a small collec-
tion of squamous epithelial cells in the middle ear that normally
undergoes apoptosis before or shortly after birth. Congenital choles-
teatoma can grow laterally and erode through the tympanic mem-
brane, and at that point, it can be difficult to differentiate congenital
from acquired disease.
Cholesteatoma is a rare disorder (1:10 000 per year),1 and there-
fore, epidemiological studies are difficult to conduct, and causative
risk factors are still poorly understood. The citations about choles-
teatoma in the definitive catalogue of genes and genetic diseases,
Online Mendelian Inheritance in Man,12 document minimal evidence
for the Mendelian inheritance of this disorder.13 However, reports of
familial clustering of disease and of association with genetic syn-
dromes (reviewed here) suggest underlying, but as yet unidentified
genetic risk factors. Identifying these could enhance our understand-
ing of disease biology, and open up pathways for diagnostic, screen-
ing and therapeutic interventions.
One way to identify candidate genetic factors is through anal-
ysis of products of gene expression in pathological specimens.
There are two published large-scale analyses comparing RNA tran-
script expression in cholesteatoma to that in skin of the external
auditory canal. These have shown several hundred genes are dif-
ferentially regulated in cholesteatoma samples, including genes
with products involved in growth, differentiation, signal transduc-
tion, cell communication, protein metabolism and cytoskeleton for-
mation.14,15 However, the results from these studies are
inconsistent, and are measuring gene expression once cholestea-
toma has formed, and so have failed to significantly further our
understanding of constitutional risk.
Here, we describe findings from a systematic review of the
genetics of congenital and acquired cholesteatoma. Our aims from
this review were to describe how susceptibility is transmitted within
families showing disease clustering, to better understand the genetic
architecture of disease, and to document any genotypes shown to
co-segregate with the cholesteatoma phenotype. We also aimed to
classify genetic syndromes associated with increased risk of choles-
teatoma, which may implicate candidate genetic loci for further
investigation.
2 | MATERIALS AND METHODS
2.1 | Objectives
To synthesise published evidence that addresses the following questions:
1. Can the development of a cholesteatoma be described as a heri-
table trait, or is there a genetic predisposition to cholesteatoma
within some families?
2. Have any genetic alterations or congenital syndromes been asso-
ciated with cholesteatoma?
2.2 | Registration of systematic review method
The protocol was registered with the PROSPERO Interna-
tional prospective register of systematic reviews database in June
2015.16
Keypoints
• We have synthesised data from 35 published studies in
the first systematic review about the genetics of choles-
teatoma.
• Only low quality evidence from case reports, case series,
and small epidemiological studies was identified.
• Familial clustering suggests a possible genetic component
to risk of cholesteatoma, and evidence from congenital
syndromes suggests this could relate to loci regulating
ear embryology.
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2.3 | Search strategy
We searched the MEDLINE (EBSCO), OMIM (http://www.ncbi.nlm.
nih.gov/omim) and Public Health genomics Knowledge Base (https://
phgkb.cdc.gov/HuGENavigator/startPagePhenoPedia.do) from 1980
to July 2015 using the terms “Cholesteatoma” AND “famil* (OR
Gene* OR hered* OR inherit* OR syndrom* OR kindred OR pedi-
gree OR oncogene* OR tumour suppressor OR tumor suppressor
OR epigenetic* OR mutat* OR somatic OR homeobox).” We supple-
mented the search with relevant references identified in the citation
lists at the article review stage.
2.4 | Inclusion and exclusion criteria
Studies were identified from the titles and abstracts by the primary
reviewer (BAJ) and secondary reviewer (GW) using the following
inclusion criteria:
1. Primary studies of kindreds that provide information about famil-
ial clustering.
2. Primary epidemiological studies that provide evidence of heri-
tability including ethnic differences.
3. Relevant systematic reviews that provide information about
genetics or heredity for cholesteatoma.
4. Case reports that refer to familial clustering of the cholesteatoma
phenotype (>1 family member affected).
5. Case reports or epidemiological studies that provide evidence of
association between cholesteatoma and syndromes
Studies were excluded if they were general narrative reviews or
opinion pieces, about non-human or experimental disease models, or
described pathologies other than cholesteatoma.
2.5 | Study selection & data extraction
Full reports of potentially relevant articles were retrieved, and data
were extracted by the primary reviewer (BAJ). The study design,
patient characteristics and nature of the outcomes were collated and
coded red for exclusion, green for inclusion and amber to indicate
uncertainty (RAG review). When there were uncertainties about
inclusion or data interpretation, the articles were discussed by the
reviewers (GW, MB and BAJ) to reach consensus. All studies that
met the inclusion criteria were included regardless of quality, which
was subsequently appraised (see Risk of bias and quality assessment
below).
2.6 | Data synthesis
A narrative synthesis was conducted to explore the review questions
about heritability and genetic associations reported for the choles-
teatoma phenotype. We tabulated the date of the study, first author,
study design, number of subjects, subtype of cholesteatoma, genetic
investigations (including family history), associated congenital
syndromes, gene nomenclature and direct quotations from discussion
or conclusions.
2.7 | Risk of bias and quality assessment
We appraised quality of epidemiological studies by reference to the
Strengthening Reporting of Observational Studies (STROBE) guideli-
nes17 and the Strengthening Reporting of Genetic association Stud-
ies (STREGA) guidelines.18 We mapped the evidence for each study
to the five levels of evidence described by the Oxford Centre for
Evidence Based Medicine.19
3 | RESULTS
3.1 | Study selection & data extraction
Our search identified 449 unique studies, of which 36 met the initial
inclusion criteria. Most studies were excluded at the abstract or pri-
mary manuscript review stage, but six manuscripts were excluded at
the data extraction stage because there were no relevant primary data
identified about cholesteatoma or genetic phenomena,20-23 or because
the study described external auditory canal cholesteatoma.24 The
studies identified in the initial search were supplemented by five
additional reports identified by hand-searching citation lists.25-29
Thirty-five studies were finally included in this narrative synthesis (see
Figure 1 for a flow chart which summarises these steps).
3.2 | Familial clustering
Nine studies (classified as case reports, case series and epidemiologi-
cal studies) present evidence for familial clustering of cholestea-
toma.25,27,28,30-35 The extracted study characteristics are described
in Table 1.
3.3 | Congenital syndromes and cholesteatoma
Twenty-two case reports and epidemiological studies describe the
occurrence of cholesteatoma in patients affected by congenital and
malformation syndromes,13,26,30,35-52 several of which have a known
underlying genetic aetiology. These are summarised in Table 2.
Some of these reports are of cholesteatoma occurrence in a sin-
gle case of a particular syndrome, for example Beckwith-Wiedemann
syndrome, granulomatosis with polyangiitis, Nager syndrome, primary
ciliary dyskinesia, Tolosa-Hunt syndrome, Treacher Collins syndrome
and Wolf-Hirschhorn syndrome. Single occurrences of a disease,
whether associated with a syndrome or not, are susceptible to publi-
cation bias and so do not add to understanding of disease risk in iso-
lation.
3.4 | Candidate genes and gene variants
We identified just two published studies of DNA-based laboratory
investigations of particular gene sequences considered in association
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with the cholesteatoma phenotype. One is a case report of a 6-year-
old boy with a congenital cholesteatoma who was shown to have a
deletion in the APC tumour suppressor gene.53 The other is a candi-
date gene association study of polymorphisms of the GJB2 and GJB6
loci that encode connexins54 in a cohort of 98 children undergoing
surgery for cholesteatoma. These studies are also described in
Table 3.
3.5 | Risk of bias and quality assessment
We identified only a small body of literature that was relevant to
our questions about a heritable component for cholesteatoma aetiol-
ogy. Many of the studies provide some indirect evidence only, given
that the authors’ objectives were to describe cholesteatoma manage-
ment or associated environmental factors.
Most of the studies identified in the literature search, and
described here, are case reports and so represent the lowest level of
evidence. Case reports were automatically categorised as level 5 (see
Tables 1, 2 and 3). The remaining observational studies include case
series, cross-sectional surveys, case-control studies and cohort stud-
ies; each of these manuscripts was reviewed by BAJ and GW to
define the level of evidence presented; STROBE and STREGA guide-
lines were referred to in classifying the quality of the methodology
used in the case-control and cohort studies. The level of evidence
ranged from 4 (for low-quality case-control studies, surveys and case
series) and 2b for a high-quality cohort study35,49 (see Tables 1, 2
and 3).
4 | DISCUSSION
This is the first systematic review to explore the constitutional
genetics of individuals affected by cholesteatoma. We have synthe-
sised data from 35 published studies about familial aggregation of
disease. The association of cholesteatoma with congenital syndromes
and genes that were directly analysed in patients with cholesteatoma
were also considered.
4.1 | Heritability
We have summarised the published evidence about the heritability
of acquired and congenital cholesteatomas. We only identified a few
case reports and case series that show two or more affected first-
degree relatives; therefore, there is insufficient evidence to describe
cholesteatoma as a heritable trait.
However, there are some compelling individual observations to
consider, including affected monozygotic27 and dizygotic twins,28,33
families with two or more affected generations,30,32,33 and high rates
of bilateral disease in affected families.28,33 Such observations sug-
gest rare genetic variants underlie the disease in some families.
F IGURE 1 The identification and
screening of studies for inclusion in the
narrative synthesis is illustrated in this
PRISMA flow diagram. OMIM: Online
Mendelian Inheritance in Man.12
Phenopedia is an information database
curated by the US Center for Disease
Control (CDC)
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TABLE 1 Familial clustering of the cholesteatoma phenotype
Year of
publication First author Study design
Number of
subjects
Phenotypes
CC = congenital
cholesteatoma
AC = acquired
cholesteatoma
Author conclusions
extracted from
manuscript (original
language in parentheses)
Level of
evidence
1973 Ray, J. Case reports 2 siblings Intramastoid
CC in two brothers
aged 3 years, and
8.5 months.
“First, and above all, the
cholesteatomas are
considered to be
congenital.. (D’abord et
surtout parce qu’elles
sont a inscrire au
repertoire des
cholesteatomes
congenitaux..)”
5
1986 Lipkin, A.F. Case reports 2 A mother and her
daughter had CC
treated at age 5.
“These two cases may
represent a unique
variant of branchio-oto
dysplasia.”
5
1986 Podoshin, L. Prospective
cross-sectional
survey of Kibbutz
population
3056 individuals;
12 (0.4%) had
a cholesteatoma.
Unilateral
cholesteatoma in
11 cases; bilateral
disease in one case.
No data presented
on congenital/
acquired subtypes
but histological
examination of
surgical tissue
was carried out
to confirm diagnoses.
“Among cholesteatoma
patients a family history
was found in 64%. . .
One or more of their
close family members
had chronic otitis media
or cholesteatoma.”
4
1986 Naito, Y. Case reports 2 siblings Bilateral
cholesteatoma in
one dizygotic twin
and unilateral
cholesteatoma
in other. Developed
on a background of
long-standing otitis
media with effusion.
“More dizygotic and
monozygotic twins with
cholesteatoma should
be studied to decide
whether hereditary
factors have any
significant influence on
the occurrence of this
disease.”
5a
2007 Homoe, P. Case series Family; two parents
and seven siblings.
Mother and three
siblings have AC;
all surgically treated.
All five family
members seen
had a dolicocephal
appearance.
“to our knowledge this is
the first report in the
world literature of
family clustering of AC.”
4
2009 Prinsley, P. Case series 15 families with
≥2 family members
affected by
cholesteatoma.
“no distinction is made
but the majority had
drum abnormalities
and would not
therefore normally be
considered congenital.”
“this observation of
family clustering in East
Anglia is remarkable.”
“It supports the
suggestion that a
genetic predisposition
exists for
cholesteatoma.”
4
2013 Al Balushi,
T. 2013
Case reports 2 CC “we report congenital
cholesteatoma in
identical twins, a
previously unreported
occurrence.”
5
(Continues)
JENNINGS ET AL. | 5
If a disease is inherited as a monogenic or oligogenic trait, next
generation sequencing (NGS) studies55 can now be used to identify
DNA variants that are co-inherited with that trait. NGS studies of
affected family members may reveal mutations that are unique to a
single kindred (these are known as private mutations). But such find-
ings can also be generalisable if they identify the genes and biologi-
cal pathways that are altered in other cholesteatoma patients with
more complex aetiologies.
Observations about the familial aggregation of phenotypes
are often followed by more discriminating epidemiological meth-
ods to distinguish the influence of heritability from shared envi-
ronments. But because cholesteatoma is rare, a classical twin
study has not been conducted and is not feasible. However, a
study or register to collect data about bilateral disease might pro-
vide information about a genetic component to the aetiology of
cholesteatoma. The incidence of bilateral disease for individuals
could be compared to the coincidence of disease in dizygotic
twins, in a manner analogous to studies of monozygotic vs dizy-
gotic twins.
4.2 | Congenital syndromes
Several lines of evidence suggest that variants in genes regulating
ear embryogenesis and tissue architecture also increase the risk of
cholesteatoma. For example, congenital cholesteatoma is more com-
mon in the malformed ears of people with branchio-oto-renal syn-
drome.
The association of acquired cholesteatoma with Down’s syn-
drome, Turner syndrome and cleft palate is more difficult to disen-
tangle, as these syndromes also place individuals at increased risk of
COME, which often precedes development of cholesteatoma.
Whether these syndromes are in themselves associated with
increased risk of cholesteatoma is difficult to say. In contrast, Djur-
huus et al.35 showed a doubling of risk of cholesteatoma in siblings
of patients with cleft palate. This finding should nevertheless be
taken with some caution, the associated P-value was .026, which
would be considered insignificant if it had been subject to Bonfer-
roni adjustment due to the multiple hypothesis testing present in
this study.
4.3 | Gene associations
Little evidence is presented in our results about the role of particular
genes in cholesteatoma biology because only two studies reported
the analysis of gene sequences: a case report and a small candidate
gene association study. The case report describes a 6-year-old boy
affected by familial adenomatous polyposis (FAP) who had choles-
teatoma, and an inherited deletion in the tumour suppressor gene
TABLE 1 (Continued)
Year of
publication First author Study design
Number of
subjects
Phenotypes
CC = congenital
cholesteatoma
AC = acquired
cholesteatoma
Author conclusions
extracted from
manuscript (original
language in parentheses)
Level of
evidence
2013 Landegger, L.D. Case report 2. CC The index case was
diagnosed at 34 months,
his older brother was
treated for CC at
2 years of age.
“This case joins a single,
previous report
describing congenital
cholesteatoma in
multiple family
members, suggesting
that in some cases,
hereditary factors may
play a role in the
formation of the
disease.”
5
2015 Djurhuus, B.D. Historic Cohort
Study (Health
Outcomes and
demographic data
extracted from
Danish Cleft Lip and
Palate database and
the Danish National
Patient Register)
441 014 individuals
were included in
the study, comprising
8593 cases of
orofacial cleft and
6989 siblings and
a random control
group from the
Danish population.
201 and 21 Surgically
treated cholesteatomas
in a population affected
by orofacial cleft and
their siblings, respectively.
The authors note that
“in Denmark,
cholesteatomas
are rarely histologically
examined.”
“We found a twofold
increased risk of
cholesteatoma in
siblings of cleft palate
cases.”
“A possible increased
risk of cholesteatoma in
siblings of CP cases
may be explained by
familial aggregation of
subclinical muscular
defect.”
2b
Studies are presented in chronological order by year of publication.
The levels of evidence were mapped to those described by the Oxford Centre for Evidence Based Medicine.19
aData from Naito et al. extracted from abstract only.
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APC. The APC protein is expressed in many tissue types, influencing
cell migration, adhesion and morphogenesis. Loss of APC expres-
sion in the colonic epithelium leads to an imbalance of cell growth
over cell death,56but whether this is relevant to cholesteatoma
biology is not known.53 The second study was a candidate gene
association study of 98 children with cholesteatoma for variants in
the connexin gap-junction encoding genes, GJB2 and GJB6,54 some
mutations of these loci are known to lead to recessive congenital
deafness. Although the authors suggest a high frequency for some
GJB2 gene variants associated with cholesteatoma, no conclusions
can be safely drawn from this study, because it lacked a control
population and had a small sample size, placing it at risk of false
discovery.
4.4 | Limitations
We excluded non-English manuscripts and studies published before
1980 from our initial search (the earlier and/or non-English articles
were subsequently included in the narrative synthesis because they
were identified by hand-searching citation lists); it is therefore possi-
ble that we have missed relevant publications.
The over-representation of case reports, case series and histori-
cal epidemiological studies is unsurprising given that cholesteatoma
is a rare disease, but such studies provide low-level evidence in the
research hierarchy because they are usually retrospective with
incomplete data collection or follow-up, and are subject to author
bias, ascertainment bias and publication bias. In addition, such find-
ings may not be generalisable, and should be interpreted with cau-
tion, particularly with respect to theories about the underlying
aetiology of cholesteatoma.
5 | CONCLUSION
Cholesteatoma is a complex and heterogeneous clinical phenotype.
In a handful of case reports or case series, congenital and acquired
cholesteatomas have been shown to segregate within families in
the pattern typical of a monogenic or oligogenic disorder with
incomplete penetrance. The liability threshold for the observed cho-
lesteatoma phenotype could therefore depend on a combination of
environmental and genetic factors of variable penetrance. Evidence
from syndromic cases suggests that genes controlling ear morphol-
ogy may be risk factors for congenital or acquired cholesteatoma
formation.
We should accommodate the hypothesis that a range of
aetiological pathways exist for cholesteatoma and that these may
result in disease subtypes that differ in both severity and tractability.
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